Loading
BenchSci develops research software that proposes drug targets and combinations, including early laboratory work in lung cancer.
BenchSci's Emet research software combines biomedical information to propose therapeutic hypotheses. A company report describes testing four proposals in human lung squamous cell carcinoma cells and reports that two combinations produced effects exceeding the individual agents. This is company-reported, early laboratory work. It does not demonstrate that the combinations are safe or effective treatments for people.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/